Claris Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://clarisbio.com
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
Phase 1
Recruiting
- Conditions
- Limbal Stem Cell Deficiency
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Claris Biotherapeutics, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT06452316
- Locations
- 🇺🇸
Loma Linda University Eye Institute, Loma Linda, California, United States
🇺🇸Francis Price Jr, MD, Indianapolis, Indiana, United States
🇺🇸Minnesota Eye Consultants, Minnetonka, Minnesota, United States
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Claris Biotherapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06257355
- Locations
- 🇺🇸
Loma Linda University Eye Institute, Loma Linda, California, United States
🇺🇸Francis Price Jr, MD, Indianapolis, Indiana, United States
🇺🇸Minnesota Eye Consultants, Minnetonka, Minnesota, United States
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Phase 1
Completed
- Conditions
- Neurotrophic Keratitis
- Interventions
- Biological: Vehicle Control
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Claris Biotherapeutics, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT04909450
- Locations
- 🇺🇸
Loma Linda University Eye Institute, Loma Linda, California, United States
🇺🇸Gordon Schanzlin New Vision Institute, San Diego, California, United States
🇺🇸Minnesota Eye Consultants, Minnetonka, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath